Where do tirzepatide dosing protocols come from?
Tirzepatide dosing in weight management derives from the SURMOUNT phase 3 clinical trial program, which tested the molecule across thousands of adults with obesity or overweight. The trial compared three maintenance doses — 5 mg, 10 mg, and 15 mg once weekly — against placebo over 72 weeks, using a standardized titration ladder to reach each maintenance dose.
The titration schedule used in SURMOUNT-1 became the foundation for the FDA-approved Zepbound dosing protocol and, by extension, for most clinician protocols governing compounded tirzepatide. Understanding that foundation helps contextualize what any “dosing chart” actually represents: a starting point informed by controlled trial methodology, not a universal prescription.
The standard tirzepatide titration schedule
The SURMOUNT trials used the following once-weekly titration ladder. Each step lasts four weeks before the next dose increase is considered. Titration is contingent on tolerability — if gastrointestinal or other side effects are significant at a given dose, the protocol calls for holding at that dose rather than escalating.
| Weeks | Dose (once weekly) | Phase |
|---|---|---|
| 1–4 | 2.5 mg | Initial (starting dose) |
| 5–8 | 5 mg | Titration step 1 |
| 9–12 | 7.5 mg | Titration step 2 |
| 13–16 | 10 mg | Titration step 3 |
| 17–20 | 12.5 mg | Titration step 4 |
| 21+ | 15 mg | Target maintenance dose |
This table reflects the clinical trial titration protocol. Individual clinician protocols for compounded tirzepatide may differ based on patient factors and tolerability. This is not a prescription or medical advice.
The chart reflects a controlled-trial protocol; real prescribing is calibrated to your tolerability, your history, and your goal.
Why clinicians don’t always follow the published chart exactly
Clinical trial protocols are designed to produce data that is interpretable across large populations. They are standardized by design. Real-world prescribing is individualized by design.
In practice, clinicians frequently adjust tirzepatide titration for individual patients in several ways:
- Slower titration for sensitive patients: Patients who experience significant nausea, vomiting, or gastric discomfort at a given dose are often held at that dose for additional weeks before escalation. Tolerability is the primary titration signal, not a calendar schedule.
- Lower target maintenance doses: Not every patient needs to reach 15 mg. Some patients achieve their weight-management goals at 5 mg or 10 mg with good tolerability. Dose selection at steady state is a clinical judgment, not a target to hit regardless of outcome.
- Starting dose adjustment: While 2.5 mg is the standard starting dose, clinicians may modify this based on patient body weight, sensitivity history to other GLP-1 agents, and individual clinical factors.
- Dose reduction for side effect management: If side effects emerge at a higher dose that were not present at the previous dose, clinicians may step the patient back rather than persisting at the current dose.
Compounded tirzepatide concentrations and vial labeling
One practical consideration specific to compounded tirzepatide is that compounded preparations often come in concentrated vials rather than single-dose pens. Brand-name Zepbound uses single-dose autoinjector pens with a fixed dose per pen. Compounded tirzepatide vials are typically multi-dose preparations at a specified concentration (e.g., 5 mg/mL, 10 mg/mL), requiring the patient to draw the appropriate volume based on the prescribed dose.
This requires understanding the relationship between dose and volume for the specific preparation dispensed. The prescription label from a licensed 503A pharmacy should specify both the concentration and the volume to draw for each prescribed dose. When in doubt, confirm the calculation with your prescribing clinician or pharmacist before injecting.
Dosing calculation errors are one of the more common safety issues in self-administered injectable peptides. A clinician who reviews your protocol and a licensed pharmacy that labels your preparation clearly are both components of safe use.
Tirzepatide dosing and body weight
The SURMOUNT trial data showed that higher maintenance doses (10 mg and 15 mg) produced greater average weight reduction than lower doses. In SURMOUNT-1, mean weight loss over 72 weeks was approximately:
- 5 mg: approximately 15% of body weight on average
- 10 mg: approximately 19.5% of body weight on average
- 15 mg: approximately 20.9% of body weight on average
These are population averages from a controlled trial setting, not predictions for any individual patient. Individual response varies based on starting weight, metabolic factors, dietary behavior, activity level, and other variables. No specific outcome can be promised for any individual.
Why do you need a clinician for dosing — not just a chart?
The information in a dosing chart is useful context. It is not a prescription. Several clinically meaningful variables cannot be captured in a table:
- Your history with other GLP-1 agents and your GI sensitivity profile
- Other medications that may affect tirzepatide’s tolerability or the absorption timing of oral drugs
- Your starting metabolic profile and the appropriate target dose range for your goals
- Contraindications that require dose modification or preclude use of GLP-1 receptor agonists entirely
Compounded tirzepatide requires a valid prescription from a licensed clinician. That prescription reflects an individualized assessment — not a chart lookup. Learn more about clinician-prescribed tirzepatide at PepScribe.
Frequently asked questions
What is the standard starting dose for compounded tirzepatide?
The standard starting dose for tirzepatide in clinical trials was 2.5 mg once weekly. Most compounded tirzepatide protocols follow a similar starting point, though the exact dose and titration schedule are determined by the prescribing clinician based on individual patient factors. This is not a dose you should set without clinician guidance.
How is tirzepatide titrated over time?
In the SURMOUNT clinical trials, tirzepatide was titrated every 4 weeks: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg. Titration is based on tolerability. If side effects are significant at a given dose, most protocols hold at that dose rather than escalating on schedule.
What are the maximum doses used in tirzepatide clinical trials?
The SURMOUNT trials tested tirzepatide at 5 mg, 10 mg, and 15 mg once-weekly maintenance doses. The 15 mg dose showed the strongest weight management outcomes in the trial population. Brand-name Zepbound is FDA-approved at doses up to 15 mg weekly.
Is a tirzepatide dosing chart the same for everyone?
No. A published dosing chart reflects clinical trial protocols, not individualized medical advice. Your prescribing clinician will calibrate your starting dose, titration pace, and target dose based on your body weight, metabolic history, tolerability, and goals. Deviating from a clinician-prescribed schedule based on an online chart is not recommended.
How does compounded tirzepatide dosing compare to Zepbound?
Zepbound (brand-name tirzepatide) uses the same dosing schedule: starting at 2.5 mg weekly and titrating in 2.5 mg increments every 4 weeks. Compounded tirzepatide from a licensed 503A pharmacy should follow the same active molecule and dose equivalents, though the prescribing clinician determines the specific protocol for each patient.
What happens if you miss a weekly tirzepatide injection?
If a dose is missed by fewer than 4 days, take it as soon as remembered. If more than 4 days have passed, skip the missed dose and resume on the next scheduled day. Do not take two doses in the same week. Contact your prescribing clinician if you miss doses frequently, as it may affect your titration timeline.